The acquisition adds to the comprehensive biotechnology services that AIBioTech currently provides to its clients by performing assessments that examine the effects of drugs, chemicals, biologics, and other physical agents on the immune system.
ImmunoTox founder and CEO Kimber White will continue with AIBioTech as a paid consultant. ImmunoTox will operate as a division of AIBioTech.
Other key employees of ImmunoTox Inc have also accepted employment and together with acquisition of all necessary instrumentation, the ImmunoTox division will be able to continue its service offerings unabated.
AIBioTech president and chief scientific officer Dr Robert B. Harris noted the company intends to leverage the expertise of ImmunoTox into expanded service offerings for its current customers including for the first time, flow cytometry.
"The ability to monitor the immune response of the host organism is a critical component along the path of drug (and chemical) development, and by adding these services to our research support repertoire, AIBioTech becomes even more competitive as the preferred full service contract research organization," Dr Harris added.